The 16 references in paper V. Skibitsky V., Z. Sokaeva T., A. Fendrikova V., В. Скибицкий В., З. Сокаева Т., А. Фендрикова В. (2013) “ГЕНДЕРНЫЕ ОСОБЕННОСТИ ЛИПИДКОРРИГИРУЮЩЕГО И НЕФРОПРОТЕКТИВНОГО ДЕЙСТВИЯ РАЗЛИЧНЫХ ВАРИАНТОВ ГИПОЛИПИДЕМИЧЕСКОЙ ТЕРАПИИ У ПАЦИЕНТОВ С МЕТАБОЛИЧЕСКИМ СИНДРОМОМ // GENDER CHARACTERISTICS OF LIPIDOCORRECTING AND NEPHROPROTECTING EFFECTS OF DIFFERENT VARIANTS OF HYPOLIPIDEMIC THERAPY APPLICATION TO PATIENTS WITH METABOLIC SYNDROME” / spz:neicon:nefr:y:2013:i:5:p:55-61

1
Miyashita K, Itoh H, Tsujimoto H et al. Natriuretic Peptides /cGMP/ cGMP-Dependent Protein Kinase Cascades Promote Muscle Mitochondrial Biogenesis and Prevent Obesity. Diabetes
(check this in PDF content)
2
09;12 (58):2880–2892 2. Pohl MA, Blumenthal S, Cordonnier DJ et al. Independent and Additive Impact of Blood Pressure Control and Angiotensin II Receptor Blockade on Renal Outcomes in the Irbesartan Diabetic Nephropathy Trial: Clinical Implications and Limitations. J Am Soc Nephrol 2005;16: 3027–3037
(check this in PDF content)
3
Шарипова ГХ, Чазова ИЕ. Особенности поражения почек при артериальной гипертонии с наличием и отсутствием метаболического синдрома. Российский кардиологический журнал 2008; 6:1-10
(check this in PDF content)
4
Chen J, Gu D, Chen CS, Wu X. Association between the metabolic syndrome and chronic kidney disease in Chinese adults. NDT 2007; 4: 1100–1106
(check this in PDF content)
5
Sit D, Kadiroglu AK, Kayabasi H, Yilmaz M E. The prevalence of insulin resistance in nondiabetic nonobese patients with chronic kidney disease. Adv Ther 2006;23 (6): 988–998
(check this in PDF content)
6
Schaeffner ES, Kurth T, Curhan GC et al. Cholesterol and the risk of renal dysfunction in apparently healthy men. J Am Coll Nephrol 2003; 14: 2084-2091
(check this in PDF content)
7
Muntner P, Coresh J, Smith JC et al. Plasma lipids and risk of developing renal dysfunction: the atherosclerosis risk in communities study. Kidney Int 2000; 58: 293-301
(check this in PDF content)
8
Zeeuw D. Different renal protective effects of atorvastatin and rosuvastatin in diabetic and non–diabetic renal patients with proteinuria. Results of the PLANET trials». 2010 European Renal Association – European Dialysis and Transplant Association Congress; June 27, 2010; Munich, Germany
(check this in PDF content)
9
SHARP Collaborative Group. Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. Am Heart J 2010; 160;785–794
(check this in PDF content)
10
Диагностика и лечение метаболического синдрома. Российские рекомендации (второй пересмотр). Кардиоваскулярная терапия и профилактика. Приложение 2. 2009; 8(6):2-28
(check this in PDF content)
11
Функциональное состояние почек и прогнозирование сердечно-сосудистого риска. Российские рекомендации. Кардиоваскулярная терапия и профилактика. Приложение 3. 2008; 7 (6):3-24.
(check this in PDF content)
12
Смирнов АВ, Добронравов ВА, Каюков ИГ и др. Хроническая болезнь почек: основные принципы скрининга, диагностики, профилактики и подходы к лечению. Национальные рекомендации. Нефрология 2012; 16(1): 89-115
(check this in PDF content)
13
Ballantyne CM, Abate N, Yuan Z et al. Dose-Comparison Study of the Combination of Ezetimibe and Simvastatin (Vytorin) Versus Atorvastatin in Patients With Hypercholesterolemia: The Vytorin Versus Atorvastatin (VYVA) Study. Am Heart J 2005;149:464473
(check this in PDF content)
14
Sager PT, Capece R, Lipka L et al. Effects of ezetimibe coadministered with simvastatin on C-reactive protein in a large cohort of hypercholesterolemic patients. Atherosclerosis 2005;179: 361-367
(check this in PDF content)
15
Kinouchi K, Ichihara A, Bokuda K, Morimoto S, Itoh H. Effects of adding ezetimibe to fluvastatin on kidney function in patients with hypercholesterolemia: a randomized control trial. J Atheroscler Thromb. 2013;20(3):245-256
(check this in PDF content)
16
Radhakrishnan AR, Gylling Н, Tatu AМ. Cholesterol Absorption, Synthesis, and Fecal Output in Postmenopausal Women With and Without Coronary Artery Disease. Cholesterol synthesis prevails over absorption in metabolic syndrome. Arterioscler Thromb Vasc Biol 2001;21(10):1650-1655
(check this in PDF content)